ArticleFrontiers in microbiology2022
Epidemiological characteristics an outbreak of ST11 multidrug-resistant and hypervirulent
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- A systematic review of hypervirulentFrontiers in medicine · 2025Pooled it
- Genomic Analysis of HypervirulentIranian journal of biotechnology · 2026Article
- Plasmid-mediated convergence of multidrug resistance and hypervirulence in community-acquired Klebsiella pneumoniae in Tianjin, China.BMC microbiology · 2026Article
- Antimicrobial resistance, virulence defects, and evolutionary dynamics of multidrug-resistantMicrobiology spectrum · 2026Article
- The acquisition ofmBio · 2026Article
- Effects of a high proportion of cefoperazone/tazobactam on lung function and bacterial clearance rate in patients with chronic obstructive pulmonary disease and lower respiratory tract infection Klebsiella pneumoniae.European journal of medical research · 2026Article
- The dual threat of hypervirulent and multidrug-resistantFrontiers in microbiology · 2026Review
- Hypervirulent and Drug-ResistantInternational journal of general medicine · 2026Review
- A capsule-dependent lytic phage for targeting multidrug-resistant and hypervirulentApplied and environmental microbiology · 2025Article
- Genomic insights into novel ST7947 carbapenem-resistant hypervirulent Klebsiella pneumoniae: a threat from an Indian hospital setting.Annals of clinical microbiology and antimicrobials · 2025Article
- The acquisition ofbioRxiv : the preprint server for biology · 2025Article
- Genome Characterization of Carbapenem-Resistant HypervirulentMicroorganisms · 2025Article
- Characterization and genomic analysis of the highly virulentAntimicrobial agents and chemotherapy · 2025Article
- Genomic study substantiates the intensive care unit as a reservoir for carbapenem-resistantMicrobial genomics · 2024Article
- Geographical distribution, disease association and diversity ofMicrobial genomics · 2024Article
- HypervirulentPathogens & immunity · 2024Review
- Epidemiological and Molecular Characteristics of Hypermucoviscous and HypervirulentInfection and drug resistance · 2024Article
- Molecular characteristics and antimicrobial resistance profiles of Carbapenem-Resistant Klebsiella pneumoniae isolates at a tertiary hospital in Nanning, China.BMC microbiology · 2023Article
- Prevalence of multidrug-resistant hypervirulentFrontiers in microbiology · 2023Article
- Clinical Characteristics and Molecular Epidemiology of ST23Infection and drug resistance · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.